Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Mycological: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
Absorbed drug (fluconazole or ketoconazole) led to higher mycological: eradication of oral candidiasis compared with drug not absorbed from GI tract (amphotericin B or nystatin); GRADE not reported.
1 finding from 1 review
Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
Absorbed drug (fluconazole or ketoconazole) led to higher clinical: eradication of oral candidiasis compared with drug not absorbed from GI tract (amphotericin B or nystatin); GRADE not reported.
1 finding from 1 review
Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in empirical antifungal treatment compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract led to lower oral candidiasis (present) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in toxicity (adverse events probably due to drug) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs not absorbed from GI tract showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review